Movement Alert|Albemarle Rises 7.57% in Regular Trading, Q2 Earnings Beat Expectations with Raised Full-Year Guidance

Market Focus
Aug 06

On August 6, Albemarle rose 7.57% in regular trading, trading at $125.02/share, with turnover of $63.16 million.

On the news front, Albemarle reported Q2 adjusted earnings of $3.75 per diluted share, surpassing the analyst consensus estimate of $3.24 by approximately 15.7%, representing a year-over-year increase of over 3,300% from $0.11. Revenue came in at $1.743 billion, above the expected $1.603 billion, marking a 31% year-over-year increase. The company also raised its full-year specialties segment net sales guidance to $1.4 billion to $1.6 billion, with adjusted EBITDA expectations lifted to $275 million to $325 million.

Additionally, CEO Kent Masters warned that global lithium inventories are nearing depletion, with weak supply unable to meet surging demand from electric vehicles and battery energy storage. He noted that battery energy storage is expected to account for 30% of global lithium demand this year, nearly matching light EV market demand. The company also highlighted DLE technology deployment opportunities in its existing Chilean operations as a key growth pathway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10